文献速递心境障碍精神分裂症与精神病性障碍

德国边缘型人格障碍数字疗法(EPADIP-BPD):一项实用性、评估者盲法、平行组随机对照试验

A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial.
PubMed 文献 · Lancet Psychiatry · 2025-01-01

该试验在德国招募580例DSM-5边缘型人格障碍(BPD)患者,随机分入基于图式疗法的无指导数字疗法联合常规治疗(TAU)组或单纯TAU组。提示该数字疗法可能有效且无安全担忧。

要点

  • 两组其他严重不良事件无差异,未发现新的安全信号。

核心结论

  • 该试验为priovi数字疗法治疗BPD的有效性提供了初步证据,且未发现安全担忧。

研究设计与样本

  • 实用性、评估者盲法、平行组随机对照试验,在德国通过在线广告招募DSM-5 BPD且BSL-23至少中度严重的成人患者。
  • 排除主要诊断为物质使用障碍或精神病性障碍者,简单计算机化抛硬币1:1随机,无分层,评估者盲至主要结局和主要安全结局分析后。
  • 干预组接受基于图式疗法的无指导数字疗法联合TAU,对照组接受TAU加免费BPD特异性自助材料,所有患者可使用任何常规照护。
  • 主要结局为意向治疗样本3个月时BSL-23评分的时间×治疗交互作用,安全通过在线问卷评估严重不良事件数量。
  • 试验注册于德国临床试验注册中心(DRKS00028888),已完成。

主要发现

  • 患者中位年龄29岁(IQR 24-37),3个月时干预组脱落35例(12%),对照组脱落15例(5%)。

关键数值与推荐

  • 其他严重不良事件两组无差异。

临床怎么用

  • 对于DSM-5 BPD且至少中度严重的成人患者,可考虑在常规治疗基础上联合使用基于图式疗法的无指导数字疗法priovi。
  • 该数字疗法可能有助于减少自杀尝试,但需结合临床评估个体化应用。
  • 试验提供初步证据,临床推广前需进一步验证。

局限性

  • 试验为实用性设计,仅评估3个月短期结局,长期效果未知。
  • 未记录 ethnicity 数据,样本以女性为主(90%),外推性受限。
  • 数字疗法为无指导使用,依赖患者自主性,脱落率干预组(12%)高于对照组(5%)。
  • 排除主要诊断为物质使用障碍或精神病性障碍者,结果不适用于这些共病人群。
  • 作者称证据为初步性(tentative evidence),需更多研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fewer than 25% of patients with borderline personality disorder (BPD) receive guideline-adherent psychotherapy. Digital therapeutics can help reduce this gap. Therefore, we tested the effectiveness and safety of priovi, a digital therapeutic for BPD. METHODS: We conducted a pragmatic, assessor-blind, parallel-group, randomised controlled trial, recruiting patients with BPD, according to DSM-5 classification, of at least moderate severity on the 23-item Borderline Symptom List (BSL-23) via online advertisements in Germany. Patients were aged 18 years or older, agreed on an emergency plan for suicidal crises, and gave informed consent to participate. Patients were excluded if they had a primary diagnosis of a substance use disorder or a diagnosis of a psychotic disorder. Simple computerised coin-toss randomisation (1:1) without stratification was used to assign patients to either the unguided digital therapeutic based on schema therapy together with treatment as usual (TAU; intervention group) or TAU alone (control group) and study investigators were masked to group assignment until after the analysis of the primary outcome and main safety outcome. All patients could use any form of usual care. The control group received freely available BPD-specific self-help material. The primary outcome was the time by treatment interaction in the intention-to-treat sample at 3 months measured by BSL-23 score. Safety was established via the number of serious adverse events (ie, suicide attempts, other life-threatening events, and hospitalisation), assessed via online questionnaire. Individuals with BPD were involved in the development of the digital therapeutic, but not in the design of this study. The trial was registered on German Clinical Trials Register (DRKS00028888) and is completed. FINDINGS: Between May 3 and Oct 20, 2022, 1766 patients were screened for eligibility and 580 patients (520 [90%] women, 47 [8%] men, and 13 [2%] gender diverse) were randomly assigned to the intervention group (n=302) and control group (n=278). Ethnicity data were not recorded. At the primary timepoint of 3 months, 35 (12%) patients dropped out of the intervention group and 15 (5%) of the control group. The median age of patients was 29 years (IQR 24-37). Intention-to-treat analysis with linear mixed models showed a significant time by treatment interaction (p=0·0005) at 3 months in favour of the intervention group (d=0·24 [95% CI 0·07-0·42]). Regarding safety, there were significantly fewer suicide attempts in the intervention group (n=7) than in the control group (n=21; incidence rate ratio 0·34 [95% CI 0·14-0·79]; p=0·0081) and there were no differences regarding other serious adverse events. INTERPRETATION: This trial provides tentative evidence of the effectiveness and absence of safety concerns of the digital therapeutic, priovi, in the treatment of individuals with BPD. FUNDING: GAIA.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Assmann N, Jacob G, Schaich A, et al. A digital therapeutic for people with borderline personality disorder in Germany (EPADIP-BPD): a pragmatic, assessor-blind, parallel-group, randomised controlled trial. Lancet Psychiatry. 2025. PMID: 40245074. doi:10.1016/S2215-0366(25)00063-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。